Actinium Pharmaceuticals Inc (NYSE:ATNM) saw a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 2,170,107 shares, a decline of 0.0% from the October 14th total of 2,170,966 shares. Approximately 4.3% of the shares of the stock are short sold. Based on an average trading volume of 470,747 shares, the short-interest ratio is presently 4.6 days.

Shares of Actinium Pharmaceuticals (NYSE:ATNM) opened at 1.09 on Friday. The company’s market capitalization is $60.76 million. Actinium Pharmaceuticals has a 12-month low of $0.86 and a 12-month high of $3.50. The stock’s 50 day moving average is $1.11 and its 200-day moving average is $1.59.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

5 Day Chart for NYSE:ATNM

Receive News & Stock Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.